VIVET PRESENTING DURING 2019 GENE THERAPY FOR RARE DISORDERS EUROPE CONFERENCE IN LONDON
Anne Douar, Chief Development Officer of Vivet Therapeutics, will give a presentation (“Manufacturing of a New Gene Therapy Product: Long…
VIVET ATTENDING Chardan’s 3rd Annual Genetic Medicines Conference
Jean-Philippe Combal, Vivet Therapeutics’ CEO, will be hosting 1×1 meetings during Chardan ‘s 3rd Annual Genetic Medicines Conference, Oct 7-8,…
VIVET PRESENTING AT 2019 CELL & GENE MEETING ON THE MESA
Vivet Therapeutics CEO, Jean-Philippe Combal, will be giving a corporate presentation during 2019 Cell & Gene Meeting on the Mesa in Carlsbad on…
Vivet is attending the SSIEM 2019 Symposium in Rotterdam
Jean-Philippe Combal, Vivet Therapeutics’ CEO
VIVET ATTENDING BIO 2019 IN PHILADELPHIA ON JUNE 3-6
Vivet’s CEO, Jean-Philippe Combal and Thomas Daniel, BD Director, will be hosting 1×1 meetings during BIO 2019 in Philadelphia on June 3-6.
Vivet presenting at ARM 2019 Cell & Gene Meeting on the Med in Barcelona
Jean-Philippe Combal, Vivet CEO, will be attending a panel
Vivet Therapeutics Announces 2 Abstracts Accepted For Oral Presentation At 2019 ASGCT
Paris, France, April 24, 2019 – Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments
VIVET PRESENTING LEAD PRODUCT, VTX-801, AND PFIC INDICATION VTX-803, AT 2019 INTERNATIONAL LIVER CONGRESS
Vivet Therapeutics will be making a presentation on its lead product
VIVET ATTENDING 3RD ANNUAL GENE THERAPY FOR RARE DISORDERS CONFERENCE IN BOSTON
Jean-Philippe Combal, Vivet Therapeutics’ CEO, will be attending the 3rd Annual Gene Therapy for Rare Disorders conference in Boston (March 26-28 2019).
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics
